Incyte Corp (INCY):製薬・医療:M&Aディール及び事業提携情報

【英語タイトル】Incyte Corp (INCY) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

GlobalDataが出版した調査資料(DATA904C9974)・商品コード:DATA904C9974
・発行会社(調査会社):GlobalData
・発行日:2018年11月
・ページ数:85
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000を加算
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
【レポートの概要】

Summary
Incyte Corp (Incyte) is a biopharmaceutical company that discovers, develops, and commercializes proprietary cancer therapeutics. The company’s lead product, Jakafi (ruxolitinib) is marketed in the US for the treatment of patients with high-risk myelofibrosis as well as patients with polycythemia vera who are intolerant to hydroxyurea. JAKAFI is distributed principally through a network of specialty pharmacy providers and wholesalers. In collaboration with Incyte, Novartis International Pharmaceutical Ltd. (Norvatis) develops and commercializes ruxolitinib outside the US for hematologic and oncologic indications under the name Jakavi. The company’s pipeline portfolio encompasses drug indications targeted at the treatment of lung cancer, graft versus host disease, non-small cell lung cancer, multiple tumor types, b-cell malignancies, solid tumors, glioblastoma, liver cancer, and advanced malignancies. Incyte is headquartered in Wilmington, Delaware, the US.

Incyte Corp (INCY) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Incyte Corp, Pharmaceuticals & Healthcare, Deal Details 13
Asset Purchase 13
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13
Private Equity 14
TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14
Partnerships 15
Incyte and Foundation Medicine Enter into Agreement 15
Immunovaccine Enters into Agreement with Incyte 16
Incyte and Syros Pharma Enter into Agreement 17
AstraZeneca and MedImmune Expands Agreement with Incyte 18
Bristol-Myers Squibb and Incyte Enter into Agreement 19
Incyte Enters into Research Agreement with Abramson Cancer Center 20
Incyte Enters into Distribution Agreement with GENESIS Pharma 21
Incyte Enters into Agreement with Moffitt Cancer Center 22
Incyte Enters into Agreement with AstraZeneca 23
Incyte Extends Partnership with Merck 24
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25
Licensing Agreements 26
Incyte Enters into Licensing Agreement with MacroGenics 26
Incyte Enters into Licensing Agreement with Calithera Biosciences 27
Incyte Enters into Licensing Agreement with Merus 29
Incyte Amends Licensing Agreement with ARIAD Pharma 31
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32
Incyte Amends Licensing Agreement with Agenus 33
Equity Offering 35
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36
Incyte Raises USD650 Million in Public Offering of Shares 37
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38
Agenus Raises USD35 Million in Private Placement of Common Stock 40
Debt Offering 41
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 41
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 43
Acquisition 45
Gilead Sciences May Acquire Incyte 45
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46
Incyte Corp – Key Competitors 48
Incyte Corp – Key Employees 49
Incyte Corp – Locations And Subsidiaries 50
Head Office 50
Other Locations & Subsidiaries 50
Recent Developments 51
Financial Announcements 51
Sep 30, 2018: Incyte reports 2018 third quarter and nine month financial results and provides updates on key clinical programs 51
Jul 31, 2018: Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs 57
May 01, 2018: Incyte Reports 2018 First-Quarter Financial Results and Updates on Key Clinical Programs 60
Feb 15, 2018: Incyte Reports 2017 Fourth-Quarter and Year-End Financial Results, Provides 2018 Financial Guidance and Updates on Key Clinical Programs 63
Oct 31, 2017: Incyte Reports 2017 Third-Quarter Financial Results and Updates on Key Clinical Programs 66
May 04, 2017: Incyte Reports 2017 First-Quarter Financial Results and Updates on Key Clinical Programs 68
Feb 14, 2017: Incyte Reports 2016 Fourth-Quarter and Year-End Financial Results, Provides 2017 Financial Guidance and Updates on Key Clinical Programs 70
Corporate Communications 73
Sep 06, 2018: Incyte announces Chief Financial Officer David Gryska to retire at the End of 2018 73
Oct 30, 2017: Incyte Names New Member to Its Board of Directors 74
Oct 06, 2017: Incyte and Cancer Support Community Delaware Announce the Establishment of the Incyte Cancer Care Assistance Fund for Delaware 75
Product News 76
06/21/2018: Incyte to Present Data on INCB54828 at 2018 Investor and Analyst Event 76
04/20/2017: Incyte Presents Data on INCB050465 At at the 2017 ASCO Annual Meeting 77
03/07/2017: Agenus Abstract Accepted for Presentation on INCAGN01949 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 78
03/07/2017: Agenus Announces Presentation on INCAGN01876 at the American Association for Cancer Research (AACR) 2017 Annual Meeting 79
Clinical Trials 80
Nov 10, 2017: MacroGenics Announces Poster Presentations on MGA012 at 32nd Annual SITC Meeting 2017 80
Oct 19, 2017: Calithera Announces First Patient Treated in Phase 1 Cohort of INCB01158 dosed in Combination with Keytruda 81
Jun 05, 2017: CB-1158 (INCB01158) Phase I Solid Tumor Data Presented at the American Society of Clinical Oncology Annual Meeting 82
Apr 20, 2017: Incyte Presents Data on CB-1158 at the 2017 ASCO Annual Meeting 83
Mar 28, 2017: Calithera to Receive $12 Million Milestone Payment From Incyte for Achievement of Pharmacokinetic and Pharmacodynamic Goals in Phase 1 Study 84
Appendix 85
Methodology 85
About GlobalData 85
Contact Us 85
Disclaimer 85

List of Tables
Incyte Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10
Incyte Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Incyte Acquires Rights to Ruxolitinib from Eli Lilly 13
TRC Capital to Acquire Incyte in Tender Offer for USD133.32 Million 14
Incyte and Foundation Medicine Enter into Agreement 15
Immunovaccine Enters into Agreement with Incyte 16
Incyte and Syros Pharma Enter into Agreement 17
AstraZeneca and MedImmune Expands Agreement with Incyte 18
Bristol-Myers Squibb and Incyte Enter into Agreement 19
Incyte Enters into Research Agreement with Abramson Cancer Center 20
Incyte Enters into Distribution Agreement with GENESIS Pharma 21
Incyte Enters into Agreement with Moffitt Cancer Center 22
Incyte Enters into Agreement with AstraZeneca 23
Incyte Extends Partnership with Merck 24
Incyte Enters into Research Agreement with Vanderbilt University Medical Center 25
Incyte Enters into Licensing Agreement with MacroGenics 26
Incyte Enters into Licensing Agreement with Calithera Biosciences 27
Incyte Enters into Licensing Agreement with Merus 29
Incyte Amends Licensing Agreement with ARIAD Pharma 31
Incyte Enters into Licensing Agreement with Jiangsu Hengrui Medicine 32
Incyte Amends Licensing Agreement with Agenus 33
Syros Pharma Raises USD1.2 Million in Private Placement of Shares 35
Syros Pharma Plans to Raise up to USD8.4 Million in Public Offering of Shares 36
Incyte Raises USD650 Million in Public Offering of Shares 37
Calithera Biosciences Raises USD8 Million in Private Placement of Shares 38
Agenus Raises USD35 Million in Private Placement of Common Stock 40
Incyte Completes Private Placement Of Notes Due 2018 For US$375 Million 41
Incyte Completes Private Placement Of Notes Due 2020 For US$375 Million 43
Gilead Sciences May Acquire Incyte 45
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 46
Incyte Corp, Key Competitors 48
Incyte Corp, Key Employees 49
Incyte Corp, Subsidiaries 50

List of Figures
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Incyte Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Incyte Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Incyte Corp, Medical Devices Deals, 2012 to YTD 2018 10

★調査レポート[Incyte Corp (INCY):製薬・医療:M&Aディール及び事業提携情報] (コード:DATA904C9974)販売に関する免責事項を必ずご確認ください。
★調査レポート[Incyte Corp (INCY):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆